SOX10 and melanoma: Although we did not detect a statistically significant correlation between the change in the number of CD40+SOX10+ cells in the TME post-treatment and the progression free survival (PFS) due to the small sample size and complications of prior treatments, we observed a clear trend for a positive correlation for D + T induction of CD40+SOX10+ cells for the 6 melanoma patients studied who had not undergone any treatment prior to BRAF/MEK inhibitor therapy (Spearman r = 0.3143).